F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, and a Novo Ventures portfolio company. has secured $60.8 million in new financing from new and existing investors. 12 August 2020
Anglo-Swedish pharma major AstraZeneca has entered into an agreement with Chinese vaccine manufacturer Shenzhen Kangtai to produce its COVID-19 vaccine candidate AZD1222, when approved, in China by the end of 2020. 10 August 2020
US biotech Moderna revealed on Wednesday that smaller volume agreements for its investigational COVID-19 vaccine mRNA-1273 have been executed at between $32 and $37 per dose. or up to $74 for a full course. 6 August 2020
GentiBio, a biopharma company developing engineered regulatory T cells that restrict inflammation in specific tissues, announced today the launch of the company with $20 million seed funding from OrbiMed, Novartis Venture Fund and RA Capital Management. 5 August 2020
HUYA Bioscience, a global firm specializing in biopharma opportunities originating in China, has exclusively licensed global ex-China rights to the SHP2 inhibitor, HBI-2376. 4 August 2020
Californian firm IDEAYA Biosciences has announced the regulatory clearance of its collaboration partnership with GlaxoSmithKline, which includes an upfront cash payment of $100 million from GSK. 4 August 2020
Singapore-based ASLAN Pharmaceuticals has appointed a new chief medical officer, Kenneth Kobayashi, formerly senior medical director at Eli Lilly subsidiary Dermira. 3 August 2020
Blueprint Medicines' Ayvakit (avapritinib), a treatment for gastrointestinal stromal tumors (GIST), was put on the list for priority review by China's Center for Drug. Evaluation (CDE). 29 July 2020
Milan’s Enthera Pharmaceuticals has raised 28 million euros ($33 million) in a series A financing round. The firm is working on stem cell-based therapies for autoimmune conditions. 28 July 2020
Innovative biotech companies will be able to apply for access to a share of £30 million ($39 million) in grant funding through the UK’s relaunched Biomedical Catalyst. 27 July 2020
Novartis’ generics business, Sandoz, is to undertake a joint investment with the Austrian government to boost antibiotics manufacturing in Europe. 27 July 2020
Swedish Orphan Biovitrum, also known as Sobi, said that, following the negative opinion recommending a refusal to its marketing authorization application (MAA) by the European Medicines Agency’s Committee for Medicinal Products for Human use (CHMP) for its emapalumab, the company will apply for a re-examination. 27 July 2020
On the evening prior to the presentation of its second quarter results, US biotech Biogen announced that its chief financial officer Jeffrey Capello would be stepping down. 22 July 2020
CureVac AG, a clinical-stage German biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, has announced the closing of its latest private financing round, raising a total of $640 million (560 million euros). 22 July 2020
Partners Pfizer and BioNTech have announced initial data from their ongoing German Phase I/II, open-label, non-randomized, non-placebo-controlled, dose-escalation trial, that is part of the global mRNA-based vaccine program against SARS-CoV-2. 20 July 2020
China-based clinical stage biopharma firm JW Therapeutics, which is focused on developing, manufacturing and commercializing cell therapies for patients in China, today announced the acquisition of Syracuse Biopharma (Hong Kong) Limited. 20 July 2020
Florida, USA-based private clinical-stage biopharma Cytocom today announced the acquisition of ImQuest Life Sciences, a research and development company focused specifically on cancer, inflammation and infectious disease treatments, including its subsidiaries in an all-stock transaction. 20 July 2020
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024